Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.

  title={Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.},
  author={Deborah A. Thomas},
  journal={Hematology. American Society of Hematology. Education Program},
Significant advances in the treatment of Philadelephia chromosome (Ph)- or BCR-ABL-positive acute lymphocytic leukemia (ALL) have been made since the discovery of the selective ABL tyrosine kinase inhibitors (TKIs). Whereas the outcome with standard chemotherapy was previously dismal, incorporation of imatinib mesylate into frontline therapy has improved relapse-free and overall survival. The benefit of imatinib extends particularly to instances where allogeneic stem cell transplantation in… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 22 extracted citations


Publications referenced by this paper.
Showing 1-10 of 65 references

Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract

  • DA Thomas, HM Kantarjian, J Cortes
  • Blood
  • 2006
Highly Influential
4 Excerpts

Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib [abstract

  • C Gambacorti-Passerini, T Brummendorf, H Kantarjian
  • Proc Am Clin Soc Oncol
  • 2007

Similar Papers

Loading similar papers…